Compare Synchrony Financial (SYF) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synchrony Financial vs TransMedics Group Inc — how do they compare? Synchrony Financial trades at $77.79 (market cap $25.17B), while TransMedics Group Inc trades at $86.5 (market cap $3.00B). The key difference: Synchrony Financial is far larger — about 8.4× TransMedics Group Inc's market cap, and Synchrony Financial pays a 1.76% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| SYF | TMDX | |
|---|---|---|
Market Cap | $25.17B | $3.00B |
Sector | Financials | Technology |
52-Week High | $88.47 | $150.42 |
52-Week Low | $63.78 | $61.99 |
Dividend Yield | 1.76% | — |
Enterprise Value | — | $3.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synchrony Financial (SYF) trades at $78.62, down 1.63% on the day, with a neutral technical signal. The stock shows strong fundamentals, including a low P/E of 7.93 and a robust ROE of 22.23%, supported by three consecutive quarterly earnings beats. Recent developments include a strategic partnership with OpenAI to enhance AI-driven commerce, announced on August 17, 2026, and a dividend payment scheduled for August 17, 2026.
The outlook is positive, with a consensus price target of $87.33 suggesting 11% upside. Key opportunities include earnings momentum and AI innovation, while risks involve consumer credit deterioration and investing cash flow turning negative in 2026. Analyst sentiment is bullish, with 62.5% recommending buy.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported strong 2025 results with $605M revenue and 31.4% net margin, though 2026 projections show margin compression. Recent news highlights growth initiatives in kidney transplantation and European markets, alongside ongoing legal investigations into fiduciary duties.
The stock offers upside to the $99.57 consensus price target, supported by analyst bullishness (69% buy ratings), but faces risks from margin pressure, legal scrutiny, and earnings misses. Revenue growth remains a key catalyst, though execution risks and investor sentiment headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
